226 related articles for article (PubMed ID: 29463937)
1. Results of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion.
Hosogi M; Morizane Y; Shiode Y; Doi S; Kumase F; Kimura S; Hosokawa M; Hirano M; Toshima S; Takahashi K; Fujiwara A; Shiraga F
Acta Med Okayama; 2018 Feb; 72(1):39-45. PubMed ID: 29463937
[TBL] [Abstract][Full Text] [Related]
2. Two-year Results of Intravitreal Ranibizumab Injections Using a Treat-and-extend Regimen for Macular Edema due to Branch Retinal Vein Occlusion.
Hosogi M; Shiode Y; Morizane Y; Kimura S; Hosokawa M; Doi S; Toshima S; Takahashi K; Fujiwara A; Shiraga F
Acta Med Okayama; 2019 Dec; 73(6):517-522. PubMed ID: 31871334
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion.
Çakmak HB; Arikan Yorgun M; Toklu Y; Mutlu M
Turk J Med Sci; 2017 Feb; 47(1):40-46. PubMed ID: 28263518
[TBL] [Abstract][Full Text] [Related]
4. Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors.
Guichard MM; Xavier AR; Türksever C; Pruente C; Hatz K
Ophthalmic Res; 2018; 60(1):29-37. PubMed ID: 29566387
[TBL] [Abstract][Full Text] [Related]
5. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
6. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
7. RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections.
Miwa Y; Muraoka Y; Osaka R; Ooto S; Murakami T; Suzuma K; Takahashi A; Iida Y; Yoshimura N; Tsujikawa A
Retina; 2017 Apr; 37(4):702-709. PubMed ID: 27471827
[TBL] [Abstract][Full Text] [Related]
8. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
Meng L; Yang M; Jiang X; Li Y; Han X
Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
[TBL] [Abstract][Full Text] [Related]
9. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
10. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
[No Abstract] [Full Text] [Related]
11. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
Nishimura T; Machida S; Tada A; Oshida E; Muto T
Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
[TBL] [Abstract][Full Text] [Related]
12. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
15. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
16. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.
Moon SY; Cho KH; Woo SJ; Park SP; Kim YK
Korean J Ophthalmol; 2018 Feb; 32(1):29-37. PubMed ID: 29376223
[TBL] [Abstract][Full Text] [Related]
19. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
[TBL] [Abstract][Full Text] [Related]
20. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
